Search Results
Your search for multiple myeloma matches 1517 pages
Showing 1501 - 1517Pomalidomide Produces ‘Impressive Results’ in Patients With Multiple Myeloma Who Are Refractory to Bortezomib and Lenalidomide
The second-generation immunomodulatory drug pomalidomide (Pomalyst) “has shown impressive results in patients with multiple myeloma who are refractory to lenalidomide and bortezomib,” according to a review of clinical data leading to the drug’s approval by the U.S. Food and Drug...
Researchers Uncover Root Cause of Multiple Myeloma Relapse
Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...
Pomalidomide Plus Low-Dose Dexamethasone Improves Survival vs High-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
Pomalidomide (Pomalyst) alone has shown limited efficacy in relapsed multiple myeloma, but synergistic effects have been noted when it is combined with dexamethasone. In a phase III trial (MM-003) reported in The Lancet Oncology, Jesus San Miguel, MD, of Universidad de Salamanca, and colleagues...
Panobinostat Combined With Bortezomib and Dexamethasone Can Recapture Responses in Heavily Pretreated Patients With Multiple Myeloma
The combination of the investigational histone deacetylase inhibitor panobinostat (Faridak) with bortezomib (Velcade) and dexamethasone was able to recapture responses in 34.5% of heavily pretreated, bortezomib-refractory patients with multiple myeloma in the phase II PANORAMA 2 trial. The 55...
Preclinical Tests May Lead to New Approach to Treat CNS Lymphoma
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open at the three campuses of Mayo Clinic ...
Gene That Helps Control Aging Is Linked to Multiple Myeloma
A telomerase RNA component gene called TERC, which is responsible for regulating the length of caps on the ends of DNA molecules and believed to be involved in the aging process, has been linked to the development of multiple myeloma, according to a study published in Nature Genetics. Researchers...
Lenalidomide plus Dexamethasone Delays Progression and Improves Survival in High-risk Smoldering Multiple Myeloma
In a study reported in The New England Journal of Medicine, María-Victoria Mateos, MD, PhD, of the Universidad de Salamanca, and colleagues compared induction lenalidomide (Revlimid) plus dexamethasone followed by maintenance lenalidomide with observation in patients with high-risk...
Height Significantly Linked to Cancer Risk in Postmenopausal Women
An analysis of data from the Women’s Health Initiative (WHI) of the height measurement at enrollment of 144,701 postmenopausal women and the risk of all cancers combined has found that 20,928 of the women had a diagnosis of one or more invasive cancers during a median follow-up of 12 years....
Cancer Survivors Might Have a Decreased Risk for Alzheimer's Disease
The results from a large cohort study of 3.5 million veterans in the Veterans Affairs (VA) Boston Healthcare System show that most types of cancer were associated with a reduced risk of developing Alzheimer’s disease of between 9% and 51%. The cancers associated with the greatest reduction in ...
New Guidelines Issued in the Treatment of Multiple Myeloma–related Bone Disease
The International Myeloma Working Group (IMWG) has developed clinical practice recommendations for the management of multiple myeloma–related bone disease based on published study data through August 2012. Consensus of the interdisciplinary panel of clinical experts on the plasma-cell...
Deep Sequencing Accurately Predicts Prolonged Survival in Multiple Myeloma Patients
A study by the Spanish Myeloma Group comparing the prognostic value of traditional response criteria and minimal residual disease measurement in patients with multiple myeloma found that a sequencing-based method called LymphoSIGHT and multiparameter flow cytometry analysis both accurately...
Breaking News on Lymphoma and Myeloma to Be Reported at European Hematology Congress in Stockholm
In order to support high-quality science, the European Hematology Association collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research. In simultaneous sessions on Thursday, June 13, during the European...
Daratumumab Receives Breakthrough Therapy Designation in Multiple Myeloma
FDA has granted daratumumab breakthrough therapy designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and...
Risk of Leukemia After Cancer Chemotherapy Persists
While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online in Blood, the Journal of the American Society of...
AACR Hosts Congressional Briefing on Cancer Progress, NIH Funding
The American Association for Cancer Research (AACR) hosted a briefing on February 12 for members of Congress and their legislative staffs that highlighted progress in cancer research and treatment as well as challenges created by decreased levels of funding. The briefing was held in the Rayburn...
FDA Approves Pomalidomide for Advanced Multiple Myeloma
The FDA approved pomalidomide (Pomalyst) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Pomalidomide, an oral immunomodulatory agent, is intended for patients who have received at least two prior therapies, including lenalidomide...
Experimental Drug Combination Selectively Destroys Lymphoma Cells
Laboratory experiments conducted by researchers at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the investigational agent ibrutinib and bortezomib (Velcade) could potentially be an effective new therapy for several forms of blood cancer, including...
